GCG and early-onset autosomal dominant Alzheimer disease: GLP-1 analogs have been repeatedly shown to cross the BBB, stimulate brain GLP-1 receptors, and modulate mitochondrial function, protein aggregation, neuroinflammation, synaptic plasticity, learning and memory in experimental models of Parkinson’s and Alzheimer’s disease (Athauda and Foltynie, 2016).